



Patient Report

Specimen ID: 075-291-4710-0

Acct #: 09134075

Phone: [REDACTED]

Rte: 18

Control ID: 67963393

FALOO, BILL

Life Extension/Natl Diagnostic

5990 N Federal Hwy

Fort Lauderdale FL 33308



Patient Details

DOB: [REDACTED] 1954

Age(y/m/d): 066 [REDACTED]

Gender: M

Patient ID: [REDACTED]

Specimen Details

Date collected: 03/16/2021 1234 Local

Date received: 03/16/2021

Date entered: 03/16/2021

Date reported: 03/17/2021 1207 ET

Physician Details

Ordering: [REDACTED]

Referring:

ID:

NPI: 1043416696

General Comments & Additional Information

Alternate Control Number: [REDACTED]

Alternate Patient ID: [REDACTED]

Ordered Items

CMP14+LP+4AC+CBC/D/Plt; PT and PTT

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
CMP14+LP+4AC+CBC/D/Plt					
Chemistries					
Glucose	97		mg/dL	65-99	01
Uric Acid	4.4		mg/dL	3.8-8.4	01
	Therapeutic target for gout patients: <6.0				
BUN	14		mg/dL	8-27	01
Creatinine	0.82		mg/dL	0.76-1.27	01
eGFR If NonAfricn Am	92		mL/min/1.73	>59	
eGFR If Africn Am	107		mL/min/1.73	>59	
BUN/Creatinine Ratio	17			10-24	
Sodium	144		mmol/L	134-144	01
Potassium	4.1		mmol/L	3.5-5.2	01
Chloride	105		mmol/L	96-106	01
Carbon Dioxide, Total	25		mmol/L	20-29	01
Calcium	9.3		mg/dL	8.6-10.2	01
Phosphorus	3.9		mg/dL	2.8-4.1	01
Protein, Total	6.3		g/dL	6.0-8.5	01
Albumin	4.6		g/dL	3.8-4.8	01
Globulin, Total	1.7		g/dL	1.5-4.5	
A/G Ratio	2.7	High		1.2-2.2	
Bilirubin, Total	0.2		mg/dL	0.0-1.2	01
Alkaline Phosphatase	35	Low	IU/L	39-117	01
LDH	102	Low	IU/L	121-224	01
AST (SGOT)	20		IU/L	0-40	01
ALT (SGPT)	18		IU/L	0-44	01
Iron	64		ug/dL	38-169	01
Lipids					01

Cholesterol, Total	102	mg/dL	100-199	01
Triglycerides	42	mg/dL	0-149	01
HDL Cholesterol	52	mg/dL	>39	01
VLDL Cholesterol Cal	11	mg/dL	5-40	

Date Issued: 03/17/21 1503 ET

FINAL REPORT

Page 1 of 3

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error, please call 800-877-5227

© 1995-2021 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00

**Patient Report**Patient: **FALOON, BILL**

Specimen ID: [REDACTED]

DOB: [REDACTED]

Patient ID: [REDACTED]

Control ID: [REDACTED]

Date collected: 03/16/2021 1234 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
LDL Chol Calc (NIH)	39		mg/dL	0-99	
T. Chol/HDL Ratio	2.0		ratio	0.0-5.0	
Please Note:					01
			T. Chol/HDL Ratio		
				Men Women	
			1/2 Avg.Risk	3.4 3.3	
			Avg.Risk	5.0 4.4	
			2X Avg.Risk	9.6 7.1	
			3X Avg.Risk	23.4 11.0	
Estimated CHD Risk	< 0.5		times avg.	0.0-1.0	
	The CHD Risk is based on the T. Chol/HDL ratio. Other factors affect CHD Risk such as hypertension, smoking, diabetes, severe obesity, and family history of premature CHD.				
					01
CBC, Platelet Ct, and Diff					01
WBC	3.6		x10E3/uL	3.4-10.8	01
RBC	4.14		x10E6/uL	4.14-5.80	01
Hemoglobin	13.2		g/dL	13.0-17.7	01
Hematocrit	38.1		%	37.5-51.0	01
MCV	92		fL	79-97	01
MCH	31.9		pg	26.6-33.0	01
MCHC	34.6		g/dL	31.5-35.7	01
RDW	12.7		%	11.6-15.4	01
Platelets	153		x10E3/uL	150-450	01
Neutrophils	52		%	Not Estab.	01
Lymphs	31		%	Not Estab.	01
Monocytes	13		%	Not Estab.	01
Eos	3		%	Not Estab.	01
Basos	1		%	Not Estab.	01
Neutrophils (Absolute)	1.9		x10E3/uL	1.4-7.0	01
Lymphs (Absolute)	1.1		x10E3/uL	0.7-3.1	01
Monocytes (Absolute)	0.5		x10E3/uL	0.1-0.9	01
Eos (Absolute)	0.1		x10E3/uL	0.0-0.4	01

Baso (Absolute)	0.1	x10E3/uL	0.0-0.2	01
Immature Granulocytes	0	%	Not Estab.	01
Immature Grans (Abs)	0.0	x10E3/uL	0.0-0.1	01

PT and PTT

INR	1.0		0.9-1.2	01
-----	-----	--	---------	----

Reference interval is for non-anticoagulated patients.

Suggested INR therapeutic range for Vitamin K

antagonist therapy:

Standard Dose (moderate intensity
therapeutic range): 2.0 - 3.0

Higher intensity therapeutic range 2.5 - 3.5

Date issued: 03/17/21 1503 ET

FINAL REPORT

Page 2 of 3

This document contains private and confidential health information protected by state and federal law.

© 1995-2021 Laboratory Corporation of America® Holdings

If you have received this document in error, please call 800-877-5227

All Rights Reserved - Enterprise Report Version: 1.00

**Patient Report**

Patient: FALON, BILL

Specimen ID: [REDACTED]

DOB: [REDACTED]

Patient ID: [REDACTED]

Control ID: [REDACTED]

Date collected: 03/16/2021 1234 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Prothrombin Time	11.0		sec	9.1-12.0	01
aPTT	31		sec	24-33	01

This test has not been validated for monitoring unfractionated heparin therapy. aPTT-based therapeutic ranges for unfractionated heparin therapy have not been established. For general guidelines on Heparin monitoring, refer to the LabCorp Directory of Services.

01	TA	LabCorp Tampa 5610 W LaSalle Street, Tampa, FL 33607-1770	Dir: Sean Farrier, MD
----	----	--	-----------------------

For inquiries, the physician may contact Branch: 800-762-4344 Lab: 800-877-5227

Date Issued: 03/17/21 1503 ET

FINAL REPORT

Page 3 of 3

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error, please call 800-877-5227

© 1995-2021 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00